Abstract
Summary
Clostridium difficile is one of the most common hospital acquired infections and in the last decade, there has been a notable increase in the incidence of clostridium difficile infection as well as the severity of the infection owing to recurrence and antibiotic resistance. Disproportionately higher incidence is seen in patients undergoing a long-term antibiotic treatment such as in patients with diseases like COPD and urinary tract infection. A rising prevalence of these diseases would subsequently accelerate the growth of the global clostridium difficile infection treatment market.
LPI (LP Information)' newest research report, the “Clostridium Difficile Infection Treatment Industry Forecast” looks at past sales and reviews total world Clostridium Difficile Infection Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Clostridium Difficile Infection Treatment sales for 2023 through 2029. With Clostridium Difficile Infection Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Clostridium Difficile Infection Treatment industry.
This Insight Report provides a comprehensive analysis of the global Clostridium Difficile Infection Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Clostridium Difficile Infection Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Clostridium Difficile Infection Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Clostridium Difficile Infection Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Clostridium Difficile Infection Treatment.
The global Clostridium Difficile Infection Treatment market size is projected to grow from US$ 704.3 million in 2022 to US$ 1060.1 million in 2029; it is expected to grow at a CAGR of 6.0% from 2023 to 2029.
Clostridium difficile infection treatment usually occurs when people have taken antibiotics for a long period of time that change the normal colon bacteria allowing the clostridium difficile bacteria to grow and produce its toxins. High CDI risk antibiotics are clindamycin, cephalosporins, and quinolones including ciprofloxacin and levofloxacin. Increasing use of these antibiotics and antimicrobials is driving the incidence of clostridium difficile infection and is likely to drive the global clostridium difficile infection treatment market over the forecast period.
This report presents a comprehensive overview, market shares, and growth opportunities of Clostridium Difficile Infection Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Injectable
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Baxter International
Sanofi
Pfizer
Novartis
Astellas Pharma
Eli Lilly
AstraZeneca
Actelion Pharmaceuticals
Mylan
LPI (LP Information)' newest research report, the “Clostridium Difficile Infection Treatment Industry Forecast” looks at past sales and reviews total world Clostridium Difficile Infection Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Clostridium Difficile Infection Treatment sales for 2023 through 2029. With Clostridium Difficile Infection Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Clostridium Difficile Infection Treatment industry.
This Insight Report provides a comprehensive analysis of the global Clostridium Difficile Infection Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Clostridium Difficile Infection Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Clostridium Difficile Infection Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Clostridium Difficile Infection Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Clostridium Difficile Infection Treatment.
The global Clostridium Difficile Infection Treatment market size is projected to grow from US$ 704.3 million in 2022 to US$ 1060.1 million in 2029; it is expected to grow at a CAGR of 6.0% from 2023 to 2029.
Clostridium difficile infection treatment usually occurs when people have taken antibiotics for a long period of time that change the normal colon bacteria allowing the clostridium difficile bacteria to grow and produce its toxins. High CDI risk antibiotics are clindamycin, cephalosporins, and quinolones including ciprofloxacin and levofloxacin. Increasing use of these antibiotics and antimicrobials is driving the incidence of clostridium difficile infection and is likely to drive the global clostridium difficile infection treatment market over the forecast period.
This report presents a comprehensive overview, market shares, and growth opportunities of Clostridium Difficile Infection Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Oral
Injectable
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Baxter International
Sanofi
Pfizer
Novartis
Astellas Pharma
Eli Lilly
AstraZeneca
Actelion Pharmaceuticals
Mylan
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Clostridium Difficile Infection Treatment Market Size 2018-2029
2.1.2 Clostridium Difficile Infection Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Clostridium Difficile Infection Treatment Segment by Type
2.2.1 Oral
2.2.2 Injectable
2.3 Clostridium Difficile Infection Treatment Market Size by Type
2.3.1 Clostridium Difficile Infection Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Clostridium Difficile Infection Treatment Market Size Market Share by Type (2018-2023)
2.4 Clostridium Difficile Infection Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Drug Stores
2.4.4 Online Sales
2.5 Clostridium Difficile Infection Treatment Market Size by Application
2.5.1 Clostridium Difficile Infection Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Clostridium Difficile Infection Treatment Market Size Market Share by Application (2018-2023)
3 Clostridium Difficile Infection Treatment Market Size by Player
3.1 Clostridium Difficile Infection Treatment Market Size Market Share by Players
3.1.1 Global Clostridium Difficile Infection Treatment Revenue by Players (2018-2023)
3.1.2 Global Clostridium Difficile Infection Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Clostridium Difficile Infection Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Clostridium Difficile Infection Treatment by Regions
4.1 Clostridium Difficile Infection Treatment Market Size by Regions (2018-2023)
4.2 Americas Clostridium Difficile Infection Treatment Market Size Growth (2018-2023)
4.3 APAC Clostridium Difficile Infection Treatment Market Size Growth (2018-2023)
4.4 Europe Clostridium Difficile Infection Treatment Market Size Growth (2018-2023)
4.5 Middle East & Africa Clostridium Difficile Infection Treatment Market Size Growth (2018-2023)
5 Americas
5.1 Americas Clostridium Difficile Infection Treatment Market Size by Country (2018-2023)
5.2 Americas Clostridium Difficile Infection Treatment Market Size by Type (2018-2023)
5.3 Americas Clostridium Difficile Infection Treatment Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Clostridium Difficile Infection Treatment Market Size by Region (2018-2023)
6.2 APAC Clostridium Difficile Infection Treatment Market Size by Type (2018-2023)
6.3 APAC Clostridium Difficile Infection Treatment Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Clostridium Difficile Infection Treatment by Country (2018-2023)
7.2 Europe Clostridium Difficile Infection Treatment Market Size by Type (2018-2023)
7.3 Europe Clostridium Difficile Infection Treatment Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Clostridium Difficile Infection Treatment by Region (2018-2023)
8.2 Middle East & Africa Clostridium Difficile Infection Treatment Market Size by Type (2018-2023)
8.3 Middle East & Africa Clostridium Difficile Infection Treatment Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Clostridium Difficile Infection Treatment Market Forecast
10.1 Global Clostridium Difficile Infection Treatment Forecast by Regions (2024-2029)
10.1.1 Global Clostridium Difficile Infection Treatment Forecast by Regions (2024-2029)
10.1.2 Americas Clostridium Difficile Infection Treatment Forecast
10.1.3 APAC Clostridium Difficile Infection Treatment Forecast
10.1.4 Europe Clostridium Difficile Infection Treatment Forecast
10.1.5 Middle East & Africa Clostridium Difficile Infection Treatment Forecast
10.2 Americas Clostridium Difficile Infection Treatment Forecast by Country (2024-2029)
10.2.1 United States Clostridium Difficile Infection Treatment Market Forecast
10.2.2 Canada Clostridium Difficile Infection Treatment Market Forecast
10.2.3 Mexico Clostridium Difficile Infection Treatment Market Forecast
10.2.4 Brazil Clostridium Difficile Infection Treatment Market Forecast
10.3 APAC Clostridium Difficile Infection Treatment Forecast by Region (2024-2029)
10.3.1 China Clostridium Difficile Infection Treatment Market Forecast
10.3.2 Japan Clostridium Difficile Infection Treatment Market Forecast
10.3.3 Korea Clostridium Difficile Infection Treatment Market Forecast
10.3.4 Southeast Asia Clostridium Difficile Infection Treatment Market Forecast
10.3.5 India Clostridium Difficile Infection Treatment Market Forecast
10.3.6 Australia Clostridium Difficile Infection Treatment Market Forecast
10.4 Europe Clostridium Difficile Infection Treatment Forecast by Country (2024-2029)
10.4.1 Germany Clostridium Difficile Infection Treatment Market Forecast
10.4.2 France Clostridium Difficile Infection Treatment Market Forecast
10.4.3 UK Clostridium Difficile Infection Treatment Market Forecast
10.4.4 Italy Clostridium Difficile Infection Treatment Market Forecast
10.4.5 Russia Clostridium Difficile Infection Treatment Market Forecast
10.5 Middle East & Africa Clostridium Difficile Infection Treatment Forecast by Region (2024-2029)
10.5.1 Egypt Clostridium Difficile Infection Treatment Market Forecast
10.5.2 South Africa Clostridium Difficile Infection Treatment Market Forecast
10.5.3 Israel Clostridium Difficile Infection Treatment Market Forecast
10.5.4 Turkey Clostridium Difficile Infection Treatment Market Forecast
10.5.5 GCC Countries Clostridium Difficile Infection Treatment Market Forecast
10.6 Global Clostridium Difficile Infection Treatment Forecast by Type (2024-2029)
10.7 Global Clostridium Difficile Infection Treatment Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Clostridium Difficile Infection Treatment Product Offered
11.1.3 Merck Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Merck Main Business Overview
11.1.5 Merck Latest Developments
11.2 Baxter International
11.2.1 Baxter International Company Information
11.2.2 Baxter International Clostridium Difficile Infection Treatment Product Offered
11.2.3 Baxter International Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Baxter International Main Business Overview
11.2.5 Baxter International Latest Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Clostridium Difficile Infection Treatment Product Offered
11.3.3 Sanofi Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Sanofi Main Business Overview
11.3.5 Sanofi Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Clostridium Difficile Infection Treatment Product Offered
11.4.3 Pfizer Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Clostridium Difficile Infection Treatment Product Offered
11.5.3 Novartis Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Information
11.6.2 Astellas Pharma Clostridium Difficile Infection Treatment Product Offered
11.6.3 Astellas Pharma Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Astellas Pharma Main Business Overview
11.6.5 Astellas Pharma Latest Developments
11.7 Eli Lilly
11.7.1 Eli Lilly Company Information
11.7.2 Eli Lilly Clostridium Difficile Infection Treatment Product Offered
11.7.3 Eli Lilly Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Eli Lilly Main Business Overview
11.7.5 Eli Lilly Latest Developments
11.8 AstraZeneca
11.8.1 AstraZeneca Company Information
11.8.2 AstraZeneca Clostridium Difficile Infection Treatment Product Offered
11.8.3 AstraZeneca Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 AstraZeneca Main Business Overview
11.8.5 AstraZeneca Latest Developments
11.9 Actelion Pharmaceuticals
11.9.1 Actelion Pharmaceuticals Company Information
11.9.2 Actelion Pharmaceuticals Clostridium Difficile Infection Treatment Product Offered
11.9.3 Actelion Pharmaceuticals Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Actelion Pharmaceuticals Main Business Overview
11.9.5 Actelion Pharmaceuticals Latest Developments
11.10 Mylan
11.10.1 Mylan Company Information
11.10.2 Mylan Clostridium Difficile Infection Treatment Product Offered
11.10.3 Mylan Clostridium Difficile Infection Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Mylan Main Business Overview
11.10.5 Mylan Latest Developments
12 Research Findings and Conclusion